請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27300
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江福田 | |
dc.contributor.author | Sir-Chen Lin | en |
dc.contributor.author | 林斯晨 | zh_TW |
dc.date.accessioned | 2021-06-12T18:00:33Z | - |
dc.date.available | 2008-02-20 | |
dc.date.copyright | 2008-02-20 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-01-27 | |
dc.identifier.citation | Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539-53.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med. 1999;16:442-3. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-7. Bossé Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Després JP, Vohl MC. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med. 2002;4:311-5. Bossé Y, Després JP, Bouchard C, Pérusse L, Vohl MC. The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. Obes Res. 2003;11:809-16. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke. 2006; 37:1060-4. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ. Effects of PPAR alpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics. 2004;14:61-71. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Metabolic syndrome as a risk factor for coronary heart disease and stroke: an 11-year prospective cohort in Taiwan community. Atherosclerosis. 2007;194:214-21. Cohen JB, Levinson AD. A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature. 1988;334:119-24. Cooper DN, Smith BA, Cooke HJ, Niemann S, Schmidtke J. An estimate of unique DNA sequence heterozygosity in the human genome. Hum Genet. 1985; 69:201-5. Cresci S.The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opin Pharmacother. 2005;6:2577-91. Day IN, Humphries SE. Electrophoresis for genotyping: Microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem. 1994;222: 389-95. Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G, Staels B. DNA binding-independent induction of IkappaB alpha gene transcription by PPAR alpha. Mol Endocrinol. 2002;16:1029-39. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-88. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-52. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med. 2001;79:198-204. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet. 2000:947-59. Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, Schork NJ. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res. 2001;11:143-51. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res. 2007;73:269-77. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPAR alpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia. 2000;43:673-80. Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M. Peroxisome proliferator-activated receptor gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002;105:1440-5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9. Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; DAIS investigators. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14:823-9. Francis GA, Annicotte JS, Auwerx J. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol. 2003;285:H1–H9. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem. 2001;276:33471-7. Gouni-Berthold I, Krone W. Peroxisome proliferator-activated receptor alpha (PPAR alpha) and athero-sclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:513-23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:e13-8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13:322-7. Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 2001;50:2809-14. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation. 2006;113:e924-9. Hofker MH, Skraastad MI, Bergen AA, Wapenaar MC, Bakker E, Millington-Ward A, van Ommen GJ, Pearson PL. The X chromosome shows less genetic variation at restriction sites than the autosomes. Am J Hum Genet. 1986;39:438-51. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45-51. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998 ;246:370-4. Irimia M, Penny D, Roy SW. Coevolution of genomic intron number and splice sites. Trends Genet. 2007;23:321-5. Issemar I, Green S. Activation of a member of the hormone receptor superfamily by peroxisome proliferators. Nature. 1991;347:645. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM. Peroxisome proliferator–activated receptor gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105(8):950-5. Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis. 2002;163:183-92. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem. 2002;277:6838-45. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-4. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-904. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood. 2003;101:545-51. Kwok PY, Deng Q, Zakeri H, Taylor SL, Nickerson DA. Increasing the information content of STS-based genome maps: Identifying polymorphisms in mapped STSs. Genomics.1996;31:123-6. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, Froguel P. Mutation screening of the PPAR alpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000;26:393-401. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031-41. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-80. Lehrke M, Pascual G, Glass CK, Lazar MA. Gaining weight: the Keystone Symposium on PPAR and LXR. Genes Dev. 2005;19:1737-42. Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G, Carpusca I, Auwerx J, Andriantsitohaina R. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol. 2006;291:H161-6. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-50. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-31. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J. 2005;149:33-45. Nielsen EM, Hansen L, Echwald SM, Drivsholm T, Borch-Johnsen K, Ekstrøm CT, Hansen T, Pedersen O. Evidence for an association between the Leu162Val polymorphism of the PPAR[alpha] gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics. 2003;13:417-23. Pan WH, Kao MD, Tseng MS, Yen LL, Hung YT, Li LA, Hsiao SY, Yeh WT, Huang PC. Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996: Design, Contents, and Operations. Nutritional Science Journal. 1999;24:1-10. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer MD. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes. 2006;55:885-93. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-4. Privalsky ML. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol. 2004;66:315-60. Rastinejad F, Perlmann T, Evans RM, Sigler PB. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature. 1995;375:203-211. Rival Y, Benéteau N, Chapuis V, Taillandier T, Lestienne F, Dupont-Passelaigue E, Patoiseau JF, Colpaert FC, Junquéro D. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA Cell Biol. 2004;23:283-92. Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, Gaudet D, Vohl MC. Association between the PPARa-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49(9):482-9. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ. The human peroxisome proliferator-activated receptor alpha gene identification and functional characterization of two natural allelic variants. Pharmacogenetics. 2000;10:321-33. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochem Biophys Acta. 1996;1302:93-109. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-48. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA Cloning, Chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598-604. Sparso T, Hussain MS, Andersen G, Hainerova I, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Relationships between the functional PPAR alpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab. 2007;90:205-9. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR gamma activators. Nature. 1998;393:790-3. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2002;22:805-10. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM. Polyunsaturated Fatty Acids Interact with the PPARA-L162V Polymorphism to Affect Plasma Triglyceride and Apolipoprotein C-III Concentrations in the Framingham Heart Study. J Nutr. 2005;135:397-403. Tenkanen L, Mänttäri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995;92:1779-85. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, Janus ED, Lam KS, Lam TH. Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol. 2007;66:666-71. Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney J, Harmon B, Reeves EK, Brandoli C, Hansen BC, Seip RL, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP. PPAR alpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet. 2007;8:55-65. Ventor JC, et al. The sequence of the human genome. Science. 2001;291: 1304-51. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, Morgan K, Hudson TJ. Molecular scanning of the human PPAR alpha gene association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res. 2000;41:945-52. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003;52:803–11. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-72. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha gene is associated with variations in serum lipid levels. J Med Genet. 2002;39:189-91. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation. 2003;108:2393-9. Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006;290:H2187-95. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27300 | - |
dc.description.abstract | 研究背景
本研究的目的,主要是關於代謝症候群(metabolic syndrome)之遺傳因子的探討。代謝症候群的特徵是:腹部肥胖、血脂異常、高血壓、胰島素抗性、葡萄糖耐受性不良、易產生血管粥狀硬化、易發生血栓、及易造成炎症反應。過氧化體增殖劑活化受體(peroxisome proliferator-activated receptors),簡稱PPARs,為賀爾蒙受器,它位於細胞核,在許多器官,包括肝臟、心臟、腎臟、及骨骼肌,掌管調控脂肪的輸送和新陳代謝,它也與血糖的恆定息息相關。甚至與降血脂肪或血糖的藥物機轉也有相關。其中過氧化體增殖劑活化受體α(PPARα)的功能主要在調控血脂異化代謝(lipid catabolism)的過程。本研究的目的在探討過氧化體增殖劑活化受體基因中的多形性(polymorphism)是否和代謝症候群及其組成有關聯,及進一步探討過氧化體增殖劑活化受體α基因多形性與代謝症候群相關的疾病(如高血壓、糖尿病)之間的關聯。我們主要是採取病例對照研究(case-control study)的模式,來進行研究。 研究方法與材料 第一部分:我們根據民國93年衛生署代謝症候群的之臨床診斷準則定義,選擇300位代謝症候群成年病患,並選擇300位無代謝症候群成年人為對照組,這些病人我們以聚合脢連鎖反應(polymerase chain reaction,PCR)及限制酵素片段長度多型性(restriction fragment length polymorphism,RFLP)等方法,判定PPARα基因第三插入子(intron 3)的三個單一核苷多型性(single nucleotide polymorphism,SNP),分別是:IMS-JST019819 C/A、IMS-JST019815 T/C、及rs4253730 A/G。 我們計算各個SNP的對偶基因頻率(allele frequency)。統計各個SNP基因型(genotypes)在下列情況的分佈:代謝症候群,高血壓、糖尿病、及冠狀動脈疾病。以卡方檢定(Chi-square)或費雪正確機率考驗(Fisher's exact test)計算其勝數比(odds ratio)。並且以邏輯迴歸分析(logistic regression)校正可能的混淆因素(confounding factors)。除了傳統上的單位址分析,我們也以配子基因型分析(haplotype analysis)等方法,來探討多位址基因效用。在連續變項方面,如身體質量指數,三酸甘油脂,總膽固醇,低密度脂蛋白膽固醇,高密度脂蛋白膽固醇,我們也統計在各個單一核苷多型性不同基因型間是否有差異。 第二部分:我們選擇第五表現子(exon 5)的單一核苷多型性Leu162Val (rs1800206)來進行研究。共選擇40位無代謝症候群成年人,我們以聚合脢連鎖反應及限制酵素片段長度多型性之方法,來判定基因型,計算台灣人此一多型性的對偶基因頻率(allele frequency)。 第三部分:我們選擇啟動子(promoter)區域來進行研究。我們選擇20位無代謝症候群成年人,以聚合脢連鎖反應及核苷酸定序之方法,來找出啟動子區域可能的單一核苷多型性。 研究結果 本研究在第一部分的單位址分析方面,發現IMS-JST019819 C/A多型性之基因型中,AA的人得到冠狀動脈疾病的機會比CC及CA高(勝數比=1.531,p=0.038)。但是我們若以多重邏輯迴歸分析(multiple logistic regression)校正性別、年齡、高血壓、糖尿病等4項變數,來分析與冠狀動脈疾病之關聯性,我們得到的p值仍然有顯著意義(勝數比=1.777,p=0.039)。若校正性別、年齡、高血壓、糖尿病、低密度脂蛋白膽固醇,高密度脂蛋白膽固醇6項變數,我們得到的p值反而無顯著意義(勝數比=1.567,p=0.224)。我們也發現IMS-JST019815 T/C多型性,帶有CC及TC基因型的人得到糖尿病的機會比TT基因型的人低(勝數比=0.63,p=0.014)。但是我們若校正性別、年齡兩項變數,來分析與糖尿病之關聯性。呈現出的p值仍然有顯著意義(勝數比=0.596,p=0.014)。而在rs4253730 A/G多型性方面,帶有GG或AG基因型的人得到冠狀動脈疾病的機會比AA基因型的人高(勝數比=1.954,p=0.0003)。但是我們若校正性別、年齡、高血壓、糖尿病等4項變數,來分析與冠狀動脈疾病之關聯性,我們得到的p值仍然有顯著意義(勝數比=1.648,p=0.027)。若校正性別、年齡、高血壓、糖尿病、低密度脂蛋白膽固醇,高密度脂蛋白膽固醇6項變數,我們得到的p值同樣具有顯著意義(勝數比=2.388,p=0.005)。同時經由變異數分析(ANOVA)分析,我們也發現帶有G allele越多的人,有越高的低密度脂蛋白膽固醇(p=0.017)。 但是三種SNP與代謝症候群、高血壓的相關性都不顯著。三種SNP與身體質量指數、三酸甘油脂、總膽固醇、高密度脂蛋白膽固醇的相關性也都不顯著。 在多位址配子基因型頻率分析(multilocus haplotype analysis)方面,計算這三個SNP與代謝症候群、高血壓、糖尿病、冠狀動脈疾病四種情況之關聯性。整體而言,總合配子基因型分析在有病或對照組之間的差異都不顯著。而在個別配子基因型分析方面,也沒有一種組合顯示有統計學上的意義。 本研究在第二部分的結果顯示,全部40組皆為LL同型結合子(homozygote),因此估計台灣人PPARα基因第五表現子162V的對偶基因頻率可能小於1/80(即小於1.25%)。 本研究在第三部分的結果顯示,台灣人PPARα基因啟動子區域-1664至-712處可能沒有單一核苷多型性。 結論 本研究證實過PPARα基因intron 3的多形性與代謝症候群相關的疾病(糖尿病、冠狀動脈疾病)的發生有關聯性,也與低密度脂蛋白膽固醇的血中濃度有關聯性。 | zh_TW |
dc.description.abstract | Introduction
Characteristics of the metabolic syndrome are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance, prothrombotic and proinflammatory states. Patients with metabolic syndrome are at increased risk for developing diabetes mellitus (DM) and cardiovascular diseases. Peroxisome proliferator-activated receptors (PPARs) are nuclear proteins that belong to the superfamily of nuclear hormone receptors. PPARs are found in liver, heart, liver and skeletal muscle. PPARs are ligand-induced transcription factors that regulate the transcription of target genes in response to specific ligands, both synthetic and endogenous. PPARα regulates many genes involved in the uptake, transport, and oxidation of fatty acids. Therefore, PPARα is a potential candidate gene that may influence the risk of developing the metabolic syndrome. This study is aimed to find out the association between PPARα gene polymorphism and metabolic syndrome, its components or associated diseases. Methods A total of 300 patients with diagnosis of metabolic syndrome were enrolled in this study. The diagnosis of every patient is based on the criteria of Department of Health, Executive Yuan (1994). 300 controls were recruited who do not have metabolic syndrome. DNA was extracted from 10cc venous blood. Three single nucleotide polymorphisms (SNP) in intron 3: C/A (IMS-JST019819), T/C (IMS-JST019815), A/G (rs4253730) were selected from the JSNP and NCBI database. PCR-RFLP was performed to identify genotypes. We calculated the genotypes distribution and allele frequency among control groups. Chi-square was done and odds ratio was calculated concerning the association between gene polymorphism and metabolic syndrome, associated diseases such as hypertension or DM or coronary artery disease. In different genotypes, ANOVA was used to test the difference of the continuous variables, such as triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), and body mass index (BMI). Statistical significance is confirmed if p value<0.05. In addition, multilocus haplotype analysis was also done. We also select another polymorphism Leu162Val (rs1800206) over exon 5 for the second part of study. A total of 40 subjects without metabolic syndrome were genotyped by the means of PCR-RFLP. Allele frequency was calculated, too. Furthermore, in the third part of study, we focused on promoter region of this gene. There were totally 20 samples from subjects without metabolic syndrome were collected. In order to find possible SNPs in promoter region, PCR and sequencing was performed. Sequences were compared with each other to observe nucleotide variants. Results Single locus analysis revealed significant association between these three SNP and metabolic syndrome-associated diseases. SNP C/A (IMS-JST019819): For AA genotype, there was higher risk to have coronary artery disease than CC+CA group (odds ratio=1.531, p=0.038). P value was still significant after adjusting for sex, age, hypertension and DM. However, p value was not significant if we adjust sex, age, hypertension, DM, LDL and HDL; SNP T/C (IMS-JST019815): Subjects with C allele (CC+TC group) had lower probability value of DM than TT group (odds ratio=0.63, p=0.014). P value was still significant after adjusting for sex and age; SNP A/G (rs4253730): Subjects with G allele (GG+AG group) were at higher risk of developing coronary artery disease than AA group (odds ratio=1.954, p=0.0003). P value was still significant even after adjustment for sex, age, hypertension, DM, LDL and HDL. Subjects having more G alleles were also prone to have higher LDL (p=0.017); nonetheless, there was no strong correlation between these three polymorphisms and following items: metabolic syndrome, hypertension, triglyceride, total cholesterol, HDL or BMI. In multilocus haplotype analysis, concerning following 4 situations including metabolic syndrome, hypertension, DM and coronary artery disease, all the p values of omnibus likelihood ratio test were not significant, which indicated the overall haplotype frequency profile difference between cases and controls were not significant. Besides, using individual haplotype analysis, we were not able to identify any haplotype with significant p value either. In the second part of study, all the 40 samples were Leu162 homozygote. So we could predict that the actual allele frequency of 162Val is less than 1.25% among Taiwanese. In the third part of study, totally 20 sets of DNA samples were successfully sequenced. There was no identified SNP in the promoter region between nucleotide -1664 and -712 among Taiwanese. Conclusion This study demonstrated that polymorphisms of PPARα gene intron 3 might be associated with coronary artery disease, DM and LDL level. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:00:33Z (GMT). No. of bitstreams: 1 ntu-97-P93421012-1.pdf: 720915 bytes, checksum: 799b582060f7d3018e87c992c1e70c1d (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 一、 中文摘要………………………………………………1
二、 緒論……………………………………………………5 三、 研究方法與材料………………………………………14 四、 結果……………………………………………………23 五、 討論……………………………………………………33 六、 展望……………………………………………………37 七、 英文摘要………………………………………………39 八、 參考文獻………………………………………………42 九、 附錄……………………………………………………52 | |
dc.language.iso | zh-TW | |
dc.title | PPARα基因多型性與代謝症候群之關聯 | zh_TW |
dc.title | Association between PPARα Gene Polymorphism and Metabolic Syndrome | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 曾春典,楊偉勛 | |
dc.subject.keyword | 過氧化體增殖劑活化受體,代謝症候群,基因多型性, | zh_TW |
dc.subject.keyword | PPARα,metabolic syndrome,gene polymorphism, | en |
dc.relation.page | 55 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-01-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 704.02 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。